Barrington Research: Maintaining the Anika Therapeutics (ANIK.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $37.00 to $37.00.

Zhitong Finance · May 9 12:20

Barrington Research: Maintains Anika Therapeutics (ANIK.US) rating from Outperform to Outperform, target price adjusted from $37.00 to $37.00.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Barrington Research：维持Anika Therapeutics(ANIK.US)评级，由优于大市调整至优于大市评级, 目标价由37.00美元调整至37.00美元。

Barrington Research: Maintaining the Anika Therapeutics (ANIK.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $37.00 to $37.00.

Risk Disclaimer

Statement